Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development
August 20 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced the
appointment of Stanley Iyadurai, M.D., Ph.D. as Vice President of
Clinical Development. Dr. Iyadurai will be responsible for leading
Catalyst’s clinical development efforts including directing,
planning, and executing clinical activities and analyzing and
interpreting clinical trial results. Dr. Iyadurai will be reporting
to Dr. Gary Ingenito, Catalyst’s Chief Medical Officer and Head of
Regulatory Affairs.
“We are pleased to welcome Stanley to the
Catalyst team. His extensive background in clinical research will
be of significant value to us in supporting our clinical
development activities,” said Patrick J. McEnany, Chairman and
Chief Executive Officer of Catalyst Pharmaceuticals. “Stanley’s
deep expertise with neuromuscular disorders will also be an asset
to our ongoing clinical trials and the continued development of
Firdapse® for additional potential indications.”
“I am delighted to join Catalyst at such a
pivotal time in the company’s history, and I look forward to
working with the leadership team to accelerate and expand clinical
activities,” said Dr. Iyadurai. “I am excited to become an integral
part of Catalyst’s commitment to advance its research and
development activities further into debilitating neuromuscular
diseases. I look forward to integrating my clinical experience and
the neuromuscular physician network to further Catalyst’s
research.”
Dr. Iyadurai most recently served as Global
Clinical Program Director, Clinical Research and Development, at
CSL Behring, where he was responsible for managing/directing global
neurology/immunology late-phase studies. Previously, Dr. Iyadurai
was a full-time faculty member at the Ohio State University
Division of Neuromuscular Medicine, Departments of Neurology and
Pediatric Neurology at Nationwide Children’s Hospital and at Saint
Louis University in the Departments of Neurology, Pediatrics and
Pathology, where he focused on neuromuscular disorders. Dr.
Iyadurai also served as the Director of the Neuromuscular Genetics
Clinic at the Ohio State University. Dr. Iyadurai has experience in
clinical research and clinical trial experience as either the
Principal Investigator or one of the sub-Investigators in more than
40 clinical trials and has published multiple research articles in
peer-reviewed journals.
Dr. Iyadurai received M.D. and Ph.D. degrees
from the University of Minnesota.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis, and spinal muscular atrophy
(SMA) type 3. Firdapse® (amifampridine phosphate) has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug
Designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat
refractory infantile spasms. CPP-115 has been granted U.S. Orphan
Drug Designation for the treatment of infantile spasms by the FDA
and has been granted E.U. Orphan Medicinal Product Designation for
the treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including (i) whether Firdapse will ever be
approved for commercialization, (ii) whether, even if Firdapse is
approved for commercialization, Catalyst will be successful in
commercializing Firdapse, (iii) whether Catalyst will be the first
company to receive an approval for amifampridine (3,4-DAP), giving
it 5-year marketing exclusivity for its product, and (iv) those
other factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2017 and its other filings with the U.S.
Securities and Exchange Commission (SEC), could adversely affect
Catalyst. Copies of Catalyst's filings with the SEC are available
from the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024